Sun Pharmaceutical Industries and closely held Vertice Pharma’s VistaPharm unit agreed to end a lawsuit in which Sun had accused a proposed copycat of an oral solution used to treat diabetes of infringing a patent for Riomet.
- No details were provided in redacted agreement, filed Aug. 21 and approved Aug. 22 in federal court in Newark, New Jersey
- Patent expires in August 2021: FDA Orange Book
- CASE: Sun Pharmaceutical Industries Ltd. v. VistaPharm Inc., 2:19-cv-7536, U.S. District Court, District of New Jersey (Newark)
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.